Schizophrenia Research Today is a free monthly online journal that collates and summarizes the latest research about Schizophrenia, including details on paranoia, symptoms, treatment, depression, medication.

Volume 4 (2007), Issue 4 (April)

1. Additional support for linkage of schizophrenia and bipolar disorder to chromosome 3q29.
   Eur Neuropsychopharmacol, 17(6): 501-5. [Abstract] [Full-text]
2. Schizophrenia as a GSK-3 dysregulation disorder.
   Trends Neurosci, 30(4): 142-9. [Abstract] [Full-text]
3. Collinear contextual suppression in schizophrenic patients.
   Psychiatry Res, 150(3): 237-43. [Abstract] [Full-text]
4. Socio-demographic and clinical predictors of occupational status in schizophrenic psychoses--follow-up within the Northern Finland 1966 Birth Cohort.
   Psychiatry Res, 150(3): 217-25. [Abstract] [Full-text]
5. A taxometric analysis of schizophrenia symptoms.
   Psychiatry Res, 150(3): 245-53. [Abstract] [Full-text]
6. Exploring the nature of facial affect processing deficits in schizophrenia.
   Psychiatry Res, 150(3): 227-35. [Abstract] [Full-text]
7. Positive association of the Disrupted-in-Schizophrenia-1 gene (DISC1) with schizophrenia in the Chinese Han population.
   Am J Med Genet B Neuropsychiatr Genet, 144(3): 266-70. [Abstract] [Full-text]
8. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
   Eur Neuropsychopharmacol, 17(6): 456-63. [Abstract] [Full-text]
9. A significant correlation between ward temperature and the severity of symptoms in schizophrenia inpatients--a longitudinal study.
   Eur Neuropsychopharmacol, 17(6): 478-82. [Abstract] [Full-text]
10. Differential expression and parent-of-origin effect of the 5-HT2A receptor gene C102T polymorphism: analysis of suicidality in schizophrenia and bipolar disorder.
    Am J Med Genet B Neuropsychiatr Genet, 144(3): 370-4. [Abstract] [Full-text]
11. Association study of polymorphisms in the glutamate transporter genes SLC1A1, SLC1A3, and SLC1A6 with schizophrenia.
    Am J Med Genet B Neuropsychiatr Genet, 144(3): 271-8. [Abstract] [Full-text]
12. Synaptotagmin XI as a candidate gene for susceptibility to schizophrenia.
    Am J Med Genet B Neuropsychiatr Genet, 144(3): 332-40. [Abstract] [Full-text]
13. Association study between the TNXB locus and schizophrenia in a Japanese population.
    Am J Med Genet B Neuropsychiatr Genet, 144(3): 305-9. [Abstract] [Full-text]
14. Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia.
    Am J Med Genet B Neuropsychiatr Genet, 144(3): 318-24. [Abstract] [Full-text]
15. Linkage of schizophrenia with chromosome 1q32 in Korean multiplex families.
    Am J Med Genet B Neuropsychiatr Genet, 144(3): 279-84. [Abstract] [Full-text]
16. No association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and schizophrenia in a Spanish sample.
    Am J Med Genet B Neuropsychiatr Genet, 144(3): 344-6. [Abstract] [Full-text]
17. Homozygosity of the interleukin-10 receptor 1 G330R allele is associated with schizophrenia.
    Am J Med Genet B Neuropsychiatr Genet, 144(3): 347-50. [Abstract] [Full-text]
18. Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability.
    Biol Psychiatry, 61(8): 935-45. [Abstract] [Full-text]
19. No association between ADRA2A polymorphisms and schizophrenia.
    Am J Med Genet B Neuropsychiatr Genet, 144(3): 341-3. [Abstract] [Full-text]
20. Working memory related gamma oscillations in schizophrenia patients.
    Int J Psychophysiol, 64(1): 39-45. [Abstract] [Full-text]
21. Magnetic resonance imaging of the thalamus and adhesio interthalamica in twins with schizophrenia.
    Arch Gen Psychiatry, 64(4): 401-9. [Abstract] [Full-text]
22. The effects of an indigenous muscarinic drug, Betel nut (Areca catechu), on the symptoms of schizophrenia: a longitudinal study in Palau, Micronesia.
    Am J Psychiatry, 164(4): 670-3. [Abstract] [Full-text]
23. Heterogeneity of treatment effects in schizophrenia.
    Am J Med, 120(4): S26-31. [Abstract] [Full-text]
24. Alterations in serum amino acid concentrations in male and female schizophrenic patients.
    Clin Chim Acta, 380(1): 186-90. [Abstract] [Full-text]
25. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    J Psychiatr Res, 41(8): 625-34. [Abstract] [Full-text]
26. Selective anterior cingulate cortex deficit during conflict solution in schizophrenia: an event-related potential study.
    J Psychiatr Res, 41(8): 635-44. [Abstract] [Full-text]
27. Transthyretin: no association between serum levels or gene variants and schizophrenia.
    J Psychiatr Res, 41(8): 667-72. [Abstract] [Full-text]
28. Increased cerebellar vermis white-matter volume in men with schizophrenia.
    J Psychiatr Res, 41(8): 645-51. [Abstract] [Full-text]
29. Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics.
    J Psychiatr Res, 41(8): 652-8. [Abstract] [Full-text]
30. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    J Psychiatr Res, 41(8): 673-9. [Abstract] [Full-text]
31. Cognitive heterogeneity in schizophrenia.
    Curr Opin Psychiatry, 20(3): 268-72. [Abstract] [Full-text]
32. Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.
    Int Clin Psychopharmacol, 22(3): 175-8. [Abstract] [Full-text]
33. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.
    Int Clin Psychopharmacol, 22(3): 145-52. [Abstract] [Full-text]
34. A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia.
    Int Clin Psychopharmacol, 22(3): 133-6. [Abstract] [Full-text]
35. Wide spectrum modulation by KP-544 in models relevant for neuronal survival.
    Neuroreport, 18(6): 571-5. [Abstract] [Full-text]
36. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program.
    Psychiatr Serv, 58(4): 544-50. [Abstract] [Full-text]
37. The MIRECC version of the Global Assessment of Functioning scale: reliability and validity.
    Psychiatr Serv, 58(4): 529-35. [Abstract] [Full-text]
38. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.
    Psychiatr Serv, 58(4): 489-95. [Abstract] [Full-text]
39. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.
    Psychiatr Serv, 58(4): 482-8. [Abstract] [Full-text]
40. Barriers to the appropriate clinical use of medications that improve the cognitive deficits of schizophrenia.
    Psychiatr Serv, 58(4): 475-81. [Abstract] [Full-text]
41. Best practices: A systematic approach to the management of patients who refuse medications in an assertive community treatment team setting.
    Psychiatr Serv, 58(4): 457-9. [Abstract] [Full-text]
42. Best practices: The development of the Social Cognition and Interaction Training program for schizophrenia spectrum disorders.
    Psychiatr Serv, 58(4): 449-51. [Abstract] [Full-text]
43. Exploring the clinical and social determinants of prescribing anticholinergic medication for Chinese patients with schizophrenia.
    Hum Psychopharmacol, 22(3): 173-80. [Abstract] [Full-text]
44. -G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: meta-analysis plus association study.
    Brain Behav Immun, 21(4): 450-7. [Abstract] [Full-text]
45. Neurological soft signs in schizophrenia patients with obsessive-compulsive disorder.
    J Neuropsychiatry Clin Neurosci, 19(2): 145-50. [Abstract] [Full-text]
46. Brain response correlates of decisional capacity in schizophrenia: a preliminary FMRI study.
    J Neuropsychiatry Clin Neurosci, 19(2): 137-44. [Abstract] [Full-text]
47. Association between facial emotion recognition and odor identification in schizophrenia.
    J Neuropsychiatry Clin Neurosci, 19(2): 128-31. [Abstract] [Full-text]
48. Stigmatization by nurses against schizophrenia in Turkey: a questionnaire survey.
    J Psychiatr Ment Health Nurs, 14(3): 302-9. [Abstract] [Full-text]
49. Therapeutic alliance and improvements in work performance over time in patients with schizophrenia.
    J Nerv Ment Dis, 195(4): 353-7. [Abstract] [Full-text]
50. Humor appreciation deficit in schizophrenia: the relevance of basic neurocognitive functioning.
    J Nerv Ment Dis, 195(4): 325-31. [Abstract] [Full-text]
51. Measuring anxiety in patients with schizophrenia.
    J Nerv Ment Dis, 195(4): 320-4. [Abstract] [Full-text]
52. Late-onset schizophrenia in child survivors of the holocaust.
    J Nerv Ment Dis, 195(4): 315-9. [Abstract] [Full-text]
53. Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations.
    J Neurol Neurosurg Psychiatry, 78(5): 532-5. [Abstract] [Full-text]
54. Volumetric analysis of septal region in schizophrenia and affective disorder.
    Eur Arch Psychiatry Clin Neurosci, 257(3): 140-8. [Abstract] [Full-text]
55. Response inhibition and cognitive flexibility in schizophrenia with and without comorbid substance use disorder.
    Schizophr Res, 92(1): 168-80. [Abstract] [Full-text]
56. Fronto-limbic and autonomic disjunctions to negative emotion distinguish schizophrenia subtypes.
    Psychiatry Res, 155(1): 29-44. [Abstract] [Full-text]
57. CSF sub-compartments in relation to plasma osmolality in healthy controls and in patients with first episode schizophrenia.
    Psychiatry Res, 155(1): 57-66. [Abstract] [Full-text]
58. Episodic memory and neuroimaging of hippocampus and fornix in chronic schizophrenia.
    Psychiatry Res, 155(1): 21-8. [Abstract] [Full-text]
59. Rationale for emphasis on management over treatment of schizophrenia in clinical practice.
    Ann Pharmacother, 41(4): 693-5. [Abstract] [Full-text]
60. Electrophysiological insights into conceptual disorganization in schizophrenia.
    Schizophr Res, 92(1): 225-36. [Abstract] [Full-text]
61. Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders.
    Schizophr Res, 92(1): 74-84. [Abstract] [Full-text]
62. The dynamic architecture of working memory in schizophrenia.
    Schizophr Res, 92(1): 160-7. [Abstract] [Full-text]
63. Premorbid adjustment in schizophrenia--an important aspect of phenotype definition.
    Schizophr Res, 92(1): 50-62. [Abstract] [Full-text]
64. Working memory dysfunction in schizophrenia compared to healthy controls and patients with depression: evidence from event-related fMRI.
    Neuroimage, 35(4): 1551-61. [Abstract] [Full-text]
65. Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia.
    Schizophr Res, 92(1): 252-61. [Abstract] [Full-text]
66. Neuropsychological functioning in MRI-derived subgroups of schizophrenia.
    Schizophr Res, 92(1): 189-96. [Abstract] [Full-text]
67. Cognitive impairment in schizophrenia: clinical ratings are not a suitable alternative to neuropsychological testing.
    Schizophr Res, 92(1): 126-31. [Abstract] [Full-text]
68. Occipital lobe gray matter volume in male patients with chronic schizophrenia: A quantitative MRI study.
    Schizophr Res, 92(1): 197-206. [Abstract] [Full-text]
69. Self-reported empathic abilities in schizophrenia.
    Schizophr Res, 92(1): 85-9. [Abstract] [Full-text]
70. Correlates of hallucinations in schizophrenia: A cross-cultural evaluation.
    Schizophr Res, 92(1): 41-9. [Abstract] [Full-text]
71. Mental state attribution, neurocognitive functioning, and psychopathology: what predicts poor social competence in schizophrenia best?
    Schizophr Res, 92(1): 151-9. [Abstract] [Full-text]
72. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia.
    Schizophr Res, 92(1): 237-51. [Abstract] [Full-text]
73. Impaired executive performance in healthy siblings of schizophrenia patients in a population-based study.
    Schizophr Res, 92(1): 142-50. [Abstract] [Full-text]
74. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia.
    Schizophr Res, 92(1): 181-8. [Abstract] [Full-text]
75. Cognitive function in childhood and early adulthood and hospital admission for schizophrenia and bipolar disorders in Danish men born in 1953.
    Schizophr Res, 92(1): 132-41. [Abstract] [Full-text]
76. Effect of antipsychotics on pituitary gland volume in treatment-naïve first-episode schizophrenia: a pilot study.
    Schizophr Res, 92(1): 207-10. [Abstract] [Full-text]
77. Increased hemodynamic response in the hippocampus, thalamus and prefrontal cortex during abnormal sensory gating in schizophrenia.
    Schizophr Res, 92(1): 262-72. [Abstract] [Full-text]
78. PANSS rater training using Internet and videoconference: results from a pilot study.
    Schizophr Res, 92(1): 63-7. [Abstract] [Full-text]
79. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort.
    Schizophr Res, 92(1): 68-73. [Abstract] [Full-text]
80. Internal capsule, corpus callosum and long associative fibers in good and poor outcome schizophrenia: a diffusion tensor imaging survey.
    Schizophr Res, 92(1): 211-24. [Abstract] [Full-text]
81. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.
    Schizophr Res, 92(1): 90-4. [Abstract] [Full-text]
82. Problem solving skills for schizophrenia.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
83. Chlorpromazine versus placebo for schizophrenia.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
84. Intellectual functioning and memory deficits in schizophrenia.
    Compr Psychiatry, 48(3): 276-82. [Abstract] [Full-text]
85. The Behavioural Assessment of the Dysexecutive Syndrome (BADS) in schizophrenia and its relation to functional outcomes.
    Neuropsychol Rehabil, 17(2): 192-205. [Abstract] [Full-text]
86. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine.
    J Sex Marital Ther, 33(3): 203-16. [Abstract] [Full-text]
87. Emotional context processing is impaired in schizophrenia.
    Cognit Neuropsychiatry, 12(3): 259-80. [Abstract] [Full-text]
88. Creative thinking in schizophrenia: the role of executive dysfunction and symptom severity.
    Cognit Neuropsychiatry, 12(3): 235-58. [Abstract] [Full-text]
89. Pseudoneglect in schizophrenia: a line bisection study with cueing.
    Cognit Neuropsychiatry, 12(3): 222-34. [Abstract] [Full-text]
90. Delay discounting in schizophrenia.
    Cognit Neuropsychiatry, 12(3): 213-21. [Abstract] [Full-text]
91. Emotion perception and social skill over the course of psychosis: a comparison of individuals "at-risk" for psychosis and individuals with early and chronic schizophrenia spectrum illness.
    Cognit Neuropsychiatry, 12(3): 198-212. [Abstract] [Full-text]
92. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls.
    Mol Psychiatry, 12(5): 502-9. [Abstract] [Full-text]
93. Rationale for a trial of immunosuppressive therapy in acute schizophrenia.
    Mol Psychiatry, 12(5): 424-31. [Abstract] [Full-text]
94. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
    Drugs Today (Barc), 43(4): 249-58. [Abstract] [Full-text]
95. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice.
    J Neurosci, 27(17): 4519-29. [Abstract] [Full-text]
96. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.
    Aust N Z J Psychiatry, 41(4): 321-6. [Abstract] [Full-text]
97. Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia.
    Aust N Z J Psychiatry, 41(4): 308-20. [Abstract] [Full-text]
98. Six months in Aceh.
    Australas Psychiatry, 15(2): 140-3. [Abstract] [Full-text]
99. Hippocampal abnormalities and memory deficits: new evidence of a strong pathophysiological link in schizophrenia.
    Brain Res Rev, 54(1): 92-112. [Abstract] [Full-text]
100. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia.
     Psychoneuroendocrinology, 32(4): 385-91. [Abstract] [Full-text]
101. Expression pattern of STOP lacZ reporter gene in adult and developing mouse brain.
     J Neurosci Res, 85(7): 1515-27. [Abstract] [Full-text]
102. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls.
     Exp Neurol, 205(1): 241-9. [Abstract] [Full-text]

© 2004-2010 Schizophrenia Research Today. All Rights Reserved.